Background: Concomitant medications may potentially affect the outcome of cancer patients. In this sub-analysis of the ARON-2 real-world study (NCT05290038), we aimed to assess the impact of concomitant use of proton pump inhibitors (PPI), statins, or metformin on outcome of patients with metastatic urothelial cancer (mUC) receiving second-line pembrolizumab. Methods: We collected data from the hospital medical records of patients with mUC treated with pembrolizumab as second-line therapy at 87 institutions from 22 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall response rate. We carried out a survival analysis by a Cox regression model. Results: A total of 802 patients were eligible for this retrospective study; the median follow-up time was 15.3 months. PPI users compared to non-users showed inferior PFS (4.5 vs. 7.2 months, p = 0.002) and OS (8.7 vs. 14.1 months, p < 0.001). Concomitant PPI use remained a significant predictor of PFS and OS after multivariate Cox analysis. The use of statins or metformin was not associated with response or survival. Conclusions: Our study results suggest a significant prognostic impact of concomitant PPI use in mUC patients receiving pembrolizumab in the real-world context. The mechanism of this interaction warrants further elucidation.

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study / Fiala, Ondřej; Buti, Sebastiano; Takeshita, Hideki; Okada, Yohei; Massari, Francesco; Palacios, Georgia Anguera; Dionese, Michele; Scagliarini, Sarah; Büttner, Thomas; Fornarini, Giuseppe; Myint, Zin W; Galli, Luca; Souza, Vinicius Carrera; Pichler, Renate; De Giorgi, Ugo; Quiroga, María Natalia Gandur; Gilbert, Danielle; Popovic, Lazar; Grande, Enrique; Mammone, Giulia; Berardi, Rossana; Crabb, Simon J; Molina-Cerrillo, Javier; Freitas, Marcelo; Luz, Murilo; Iacovelli, Roberto; Calabrò, Fabio; Tural, Deniz; Atzori, Francesco; Küronya, Zsófia; Chiari, Rita; Campos, Saul; Caffo, Orazio; Fay, André P; Kucharz, Jakub; Zucali, Paolo Andrea; Rinck, José Augusto; Zeppellini, Annalisa; Bastos, Diogo Assed; Aurilio, Gaetano; Mota, Augusto; Trindade, Karine; Ortega, Cinzia; Sade, Juan Pablo; Rizzo, Mimma; Vau, Nuno; Giannatempo, Patrizia; Barillas, Allan; Monteiro, Fernando Sabino Marques; Dauster, Breno; Cattrini, Carlo; Nogueira, Lucas; de Carvalho Fernandes, Roni; Seront, Emmanuel; Aceituno, Luís Garcia; Grillone, Francesco; Cutuli, Hernan Javier; Fernandez, Mauricio; Bassanelli, Maria; Roviello, Giandomenico; Abahssain, Halima; Procopio, Giuseppe; Milella, Michele; Kopecky, Jindrich; Martignetti, Angelo; Messina, Carlo; Caitano, Manuel; Inman, Eva; Kanesvaran, Ravindran; Herchenhorn, Daniel; Santini, Daniele; Manneh, Ray; Bisonni, Renato; Zakopoulou, Roubini; Mosca, Alessandra; Morelli, Franco; Maluf, Fernando; Soares, Andrey; Nunes, Fernando; Pinto, Alvaro; Zgura, Anca; Incorvaia, Lorena; Ansari, Jawaher; Zabalza, Ignacio Ortego; Landmesser, Johannes; Rizzo, Alessandro; Mollica, Veronica; Sorgentoni, Giulia; Battelli, Nicola; Porta, Camillo; Bellmunt, Joaquim; Santoni, Matteo. - In: CANCER IMMUNOLOGY, IMMUNOTHERAPY. - ISSN 1432-0851. - (2023). [10.1007/s00262-023-03518-z]

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study

Buti, Sebastiano
Conceptualization
;
2023-01-01

Abstract

Background: Concomitant medications may potentially affect the outcome of cancer patients. In this sub-analysis of the ARON-2 real-world study (NCT05290038), we aimed to assess the impact of concomitant use of proton pump inhibitors (PPI), statins, or metformin on outcome of patients with metastatic urothelial cancer (mUC) receiving second-line pembrolizumab. Methods: We collected data from the hospital medical records of patients with mUC treated with pembrolizumab as second-line therapy at 87 institutions from 22 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall response rate. We carried out a survival analysis by a Cox regression model. Results: A total of 802 patients were eligible for this retrospective study; the median follow-up time was 15.3 months. PPI users compared to non-users showed inferior PFS (4.5 vs. 7.2 months, p = 0.002) and OS (8.7 vs. 14.1 months, p < 0.001). Concomitant PPI use remained a significant predictor of PFS and OS after multivariate Cox analysis. The use of statins or metformin was not associated with response or survival. Conclusions: Our study results suggest a significant prognostic impact of concomitant PPI use in mUC patients receiving pembrolizumab in the real-world context. The mechanism of this interaction warrants further elucidation.
2023
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study / Fiala, Ondřej; Buti, Sebastiano; Takeshita, Hideki; Okada, Yohei; Massari, Francesco; Palacios, Georgia Anguera; Dionese, Michele; Scagliarini, Sarah; Büttner, Thomas; Fornarini, Giuseppe; Myint, Zin W; Galli, Luca; Souza, Vinicius Carrera; Pichler, Renate; De Giorgi, Ugo; Quiroga, María Natalia Gandur; Gilbert, Danielle; Popovic, Lazar; Grande, Enrique; Mammone, Giulia; Berardi, Rossana; Crabb, Simon J; Molina-Cerrillo, Javier; Freitas, Marcelo; Luz, Murilo; Iacovelli, Roberto; Calabrò, Fabio; Tural, Deniz; Atzori, Francesco; Küronya, Zsófia; Chiari, Rita; Campos, Saul; Caffo, Orazio; Fay, André P; Kucharz, Jakub; Zucali, Paolo Andrea; Rinck, José Augusto; Zeppellini, Annalisa; Bastos, Diogo Assed; Aurilio, Gaetano; Mota, Augusto; Trindade, Karine; Ortega, Cinzia; Sade, Juan Pablo; Rizzo, Mimma; Vau, Nuno; Giannatempo, Patrizia; Barillas, Allan; Monteiro, Fernando Sabino Marques; Dauster, Breno; Cattrini, Carlo; Nogueira, Lucas; de Carvalho Fernandes, Roni; Seront, Emmanuel; Aceituno, Luís Garcia; Grillone, Francesco; Cutuli, Hernan Javier; Fernandez, Mauricio; Bassanelli, Maria; Roviello, Giandomenico; Abahssain, Halima; Procopio, Giuseppe; Milella, Michele; Kopecky, Jindrich; Martignetti, Angelo; Messina, Carlo; Caitano, Manuel; Inman, Eva; Kanesvaran, Ravindran; Herchenhorn, Daniel; Santini, Daniele; Manneh, Ray; Bisonni, Renato; Zakopoulou, Roubini; Mosca, Alessandra; Morelli, Franco; Maluf, Fernando; Soares, Andrey; Nunes, Fernando; Pinto, Alvaro; Zgura, Anca; Incorvaia, Lorena; Ansari, Jawaher; Zabalza, Ignacio Ortego; Landmesser, Johannes; Rizzo, Alessandro; Mollica, Veronica; Sorgentoni, Giulia; Battelli, Nicola; Porta, Camillo; Bellmunt, Joaquim; Santoni, Matteo. - In: CANCER IMMUNOLOGY, IMMUNOTHERAPY. - ISSN 1432-0851. - (2023). [10.1007/s00262-023-03518-z]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2958272
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 2
social impact